Retinoids and breast cancer: From basic studies to the clinic and back again
All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents i...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Garattini, Enrico [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Using regression analysis to predict the future energy consumption of a supermarket in the UK - Braun, M.R. ELSEVIER, 2014, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:40 ; year:2014 ; number:6 ; pages:739-749 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ctrv.2014.01.001 |
|---|
| Katalog-ID: |
ELV022671870 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV022671870 | ||
| 003 | DE-627 | ||
| 005 | 20230625135859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2014.01.001 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014010000004.pica |
| 035 | |a (DE-627)ELV022671870 | ||
| 035 | |a (ELSEVIER)S0305-7372(14)00002-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 620 |q VZ |
| 082 | 0 | 4 | |a 150 |a 300 |q VZ |
| 084 | |a 77.52 |2 bkl | ||
| 100 | 1 | |a Garattini, Enrico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Retinoids and breast cancer: From basic studies to the clinic and back again |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. | ||
| 520 | |a All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. | ||
| 650 | 7 | |a Treatment |2 Elsevier | |
| 650 | 7 | |a RAR/RXR |2 Elsevier | |
| 650 | 7 | |a Gene pathways |2 Elsevier | |
| 650 | 7 | |a Chemo-prevention |2 Elsevier | |
| 650 | 7 | |a Breast cancer |2 Elsevier | |
| 650 | 7 | |a Retinoic acid |2 Elsevier | |
| 700 | 1 | |a Bolis, Marco |4 oth | |
| 700 | 1 | |a Garattini, Silvio Ken |4 oth | |
| 700 | 1 | |a Fratelli, Maddalena |4 oth | |
| 700 | 1 | |a Centritto, Floriana |4 oth | |
| 700 | 1 | |a Paroni, Gabriela |4 oth | |
| 700 | 1 | |a Gianni’, Maurizio |4 oth | |
| 700 | 1 | |a Zanetti, Adriana |4 oth | |
| 700 | 1 | |a Pagani, Anna |4 oth | |
| 700 | 1 | |a Fisher, James Neil |4 oth | |
| 700 | 1 | |a Zambelli, Alberto |4 oth | |
| 700 | 1 | |a Terao, Mineko |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Braun, M.R. ELSEVIER |t Using regression analysis to predict the future energy consumption of a supermarket in the UK |d 2014 |g Amsterdam [u.a.] |w (DE-627)ELV01225004X |
| 773 | 1 | 8 | |g volume:40 |g year:2014 |g number:6 |g pages:739-749 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ctrv.2014.01.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 77.52 |j Differentielle Psychologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 40 |j 2014 |e 6 |h 739-749 |g 11 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
e g eg |
|---|---|
| matchkey_str |
garattinienricobolismarcogarattinisilvio:2014----:eiodadratacrrmaisuisoh |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
77.52 |
| publishDate |
2014 |
| allfields |
10.1016/j.ctrv.2014.01.001 doi GBVA2014010000004.pica (DE-627)ELV022671870 (ELSEVIER)S0305-7372(14)00002-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Garattini, Enrico verfasserin aut Retinoids and breast cancer: From basic studies to the clinic and back again 2014transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid Elsevier Bolis, Marco oth Garattini, Silvio Ken oth Fratelli, Maddalena oth Centritto, Floriana oth Paroni, Gabriela oth Gianni’, Maurizio oth Zanetti, Adriana oth Pagani, Anna oth Fisher, James Neil oth Zambelli, Alberto oth Terao, Mineko oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:40 year:2014 number:6 pages:739-749 extent:11 https://doi.org/10.1016/j.ctrv.2014.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 40 2014 6 739-749 11 045F 610 |
| spelling |
10.1016/j.ctrv.2014.01.001 doi GBVA2014010000004.pica (DE-627)ELV022671870 (ELSEVIER)S0305-7372(14)00002-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Garattini, Enrico verfasserin aut Retinoids and breast cancer: From basic studies to the clinic and back again 2014transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid Elsevier Bolis, Marco oth Garattini, Silvio Ken oth Fratelli, Maddalena oth Centritto, Floriana oth Paroni, Gabriela oth Gianni’, Maurizio oth Zanetti, Adriana oth Pagani, Anna oth Fisher, James Neil oth Zambelli, Alberto oth Terao, Mineko oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:40 year:2014 number:6 pages:739-749 extent:11 https://doi.org/10.1016/j.ctrv.2014.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 40 2014 6 739-749 11 045F 610 |
| allfields_unstemmed |
10.1016/j.ctrv.2014.01.001 doi GBVA2014010000004.pica (DE-627)ELV022671870 (ELSEVIER)S0305-7372(14)00002-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Garattini, Enrico verfasserin aut Retinoids and breast cancer: From basic studies to the clinic and back again 2014transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid Elsevier Bolis, Marco oth Garattini, Silvio Ken oth Fratelli, Maddalena oth Centritto, Floriana oth Paroni, Gabriela oth Gianni’, Maurizio oth Zanetti, Adriana oth Pagani, Anna oth Fisher, James Neil oth Zambelli, Alberto oth Terao, Mineko oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:40 year:2014 number:6 pages:739-749 extent:11 https://doi.org/10.1016/j.ctrv.2014.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 40 2014 6 739-749 11 045F 610 |
| allfieldsGer |
10.1016/j.ctrv.2014.01.001 doi GBVA2014010000004.pica (DE-627)ELV022671870 (ELSEVIER)S0305-7372(14)00002-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Garattini, Enrico verfasserin aut Retinoids and breast cancer: From basic studies to the clinic and back again 2014transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid Elsevier Bolis, Marco oth Garattini, Silvio Ken oth Fratelli, Maddalena oth Centritto, Floriana oth Paroni, Gabriela oth Gianni’, Maurizio oth Zanetti, Adriana oth Pagani, Anna oth Fisher, James Neil oth Zambelli, Alberto oth Terao, Mineko oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:40 year:2014 number:6 pages:739-749 extent:11 https://doi.org/10.1016/j.ctrv.2014.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 40 2014 6 739-749 11 045F 610 |
| allfieldsSound |
10.1016/j.ctrv.2014.01.001 doi GBVA2014010000004.pica (DE-627)ELV022671870 (ELSEVIER)S0305-7372(14)00002-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Garattini, Enrico verfasserin aut Retinoids and breast cancer: From basic studies to the clinic and back again 2014transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid Elsevier Bolis, Marco oth Garattini, Silvio Ken oth Fratelli, Maddalena oth Centritto, Floriana oth Paroni, Gabriela oth Gianni’, Maurizio oth Zanetti, Adriana oth Pagani, Anna oth Fisher, James Neil oth Zambelli, Alberto oth Terao, Mineko oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:40 year:2014 number:6 pages:739-749 extent:11 https://doi.org/10.1016/j.ctrv.2014.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 40 2014 6 739-749 11 045F 610 |
| language |
English |
| source |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:40 year:2014 number:6 pages:739-749 extent:11 |
| sourceStr |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:40 year:2014 number:6 pages:739-749 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Differentielle Psychologie |
| institution |
findex.gbv.de |
| topic_facet |
Treatment RAR/RXR Gene pathways Chemo-prevention Breast cancer Retinoic acid |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| authorswithroles_txt_mv |
Garattini, Enrico @@aut@@ Bolis, Marco @@oth@@ Garattini, Silvio Ken @@oth@@ Fratelli, Maddalena @@oth@@ Centritto, Floriana @@oth@@ Paroni, Gabriela @@oth@@ Gianni’, Maurizio @@oth@@ Zanetti, Adriana @@oth@@ Pagani, Anna @@oth@@ Fisher, James Neil @@oth@@ Zambelli, Alberto @@oth@@ Terao, Mineko @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV01225004X |
| dewey-sort |
3610 |
| id |
ELV022671870 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022671870</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625135859.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2014.01.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014010000004.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022671870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(14)00002-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Garattini, Enrico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Retinoids and breast cancer: From basic studies to the clinic and back again</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAR/RXR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene pathways</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemo-prevention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Retinoic acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bolis, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garattini, Silvio Ken</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fratelli, Maddalena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Centritto, Floriana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paroni, Gabriela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gianni’, Maurizio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zanetti, Adriana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pagani, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fisher, James Neil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zambelli, Alberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terao, Mineko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:40</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:739-749</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2014.01.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">40</subfield><subfield code="j">2014</subfield><subfield code="e">6</subfield><subfield code="h">739-749</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Garattini, Enrico |
| spellingShingle |
Garattini, Enrico ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid Retinoids and breast cancer: From basic studies to the clinic and back again |
| authorStr |
Garattini, Enrico |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01225004X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 620 - Engineering & allied operations 150 - Psychology 300 - Social sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Retinoids and breast cancer: From basic studies to the clinic and back again Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid Elsevier |
| topic |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid |
| topic_unstemmed |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid |
| topic_browse |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Treatment Elsevier RAR/RXR Elsevier Gene pathways Elsevier Chemo-prevention Elsevier Breast cancer Elsevier Retinoic acid |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m b mb s k g sk skg m f mf f c fc g p gp m g mg a z az a p ap j n f jn jnf a z az m t mt |
| hierarchy_parent_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| hierarchy_parent_id |
ELV01225004X |
| dewey-tens |
610 - Medicine & health 620 - Engineering 150 - Psychology 300 - Social sciences, sociology & anthropology |
| hierarchy_top_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV01225004X |
| title |
Retinoids and breast cancer: From basic studies to the clinic and back again |
| ctrlnum |
(DE-627)ELV022671870 (ELSEVIER)S0305-7372(14)00002-4 |
| title_full |
Retinoids and breast cancer: From basic studies to the clinic and back again |
| author_sort |
Garattini, Enrico |
| journal |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| journalStr |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 100 - Philosophy & psychology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
739 |
| author_browse |
Garattini, Enrico |
| container_volume |
40 |
| physical |
11 |
| class |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Garattini, Enrico |
| doi_str_mv |
10.1016/j.ctrv.2014.01.001 |
| dewey-full |
610 620 150 300 |
| title_sort |
retinoids and breast cancer: from basic studies to the clinic and back again |
| title_auth |
Retinoids and breast cancer: From basic studies to the clinic and back again |
| abstract |
All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. |
| abstractGer |
All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. |
| abstract_unstemmed |
All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
6 |
| title_short |
Retinoids and breast cancer: From basic studies to the clinic and back again |
| url |
https://doi.org/10.1016/j.ctrv.2014.01.001 |
| remote_bool |
true |
| author2 |
Bolis, Marco Garattini, Silvio Ken Fratelli, Maddalena Centritto, Floriana Paroni, Gabriela Gianni’, Maurizio Zanetti, Adriana Pagani, Anna Fisher, James Neil Zambelli, Alberto Terao, Mineko |
| author2Str |
Bolis, Marco Garattini, Silvio Ken Fratelli, Maddalena Centritto, Floriana Paroni, Gabriela Gianni’, Maurizio Zanetti, Adriana Pagani, Anna Fisher, James Neil Zambelli, Alberto Terao, Mineko |
| ppnlink |
ELV01225004X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ctrv.2014.01.001 |
| up_date |
2024-07-06T16:52:36.174Z |
| _version_ |
1803849308492005376 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022671870</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625135859.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2014.01.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014010000004.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022671870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(14)00002-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Garattini, Enrico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Retinoids and breast cancer: From basic studies to the clinic and back again</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">All-trans retinoic acid (ATRA) is the most important active metabolite of vitamin A controlling segmentation in the developing organism and the homeostasis of various tissues in the adult. ATRA as well as natural and synthetic derivatives, collectively known as retinoids, are also promising agents in the treatment and chemoprevention of different types of neoplasia including breast cancer. The major aim of the present article is to review the basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance. In the first part, an analysis of the large number of pre-clinical studies available is provided, stressing the point that this has resulted in a limited number of clinical trials. This is followed by an overview of the knowledge acquired on the role played by the retinoid nuclear receptors in the anti-tumor responses triggered by retinoids. The body of the article emphasizes the potential of ATRA and derivatives in modulating and in being influenced by some of the most relevant cellular pathways involved in the growth and progression of breast cancer. We review the studies centering on the cross-talk between retinoids and some of the growth-factor pathways which control the homeostasis of the mammary tumor cell. In addition, we consider the cross-talk with relevant intra-cellular second messenger pathways. The information provided lays the foundation for the development of rational and retinoid-based therapeutic strategies to be used for the management of breast cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">RAR/RXR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene pathways</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemo-prevention</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Retinoic acid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bolis, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garattini, Silvio Ken</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fratelli, Maddalena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Centritto, Floriana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paroni, Gabriela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gianni’, Maurizio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zanetti, Adriana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pagani, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fisher, James Neil</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zambelli, Alberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terao, Mineko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:40</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:739-749</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2014.01.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">40</subfield><subfield code="j">2014</subfield><subfield code="e">6</subfield><subfield code="h">739-749</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4027214 |